<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36980310</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>22</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Induced Pluripotent Stem Cells and Their Applications in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">971</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12060971</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in the loss of motor function in the central nervous system (CNS) and ultimately death. The mechanisms underlying ALS pathogenesis have not yet been fully elucidated, and ALS cannot be treated effectively. Most studies have applied animal or single-gene intervention cell lines as ALS disease models, but they cannot accurately reflect the pathological characteristics of ALS. Induced pluripotent stem cells (iPSCs) can be reprogrammed from somatic cells, possessing the ability to self-renew and differentiate into a variety of cells. iPSCs can be obtained from ALS patients with different genotypes and phenotypes, and the genetic background of the donor cells remains unchanged during reprogramming. iPSCs can differentiate into neurons and glial cells related to ALS. Therefore, iPSCs provide an excellent method to evaluate the impact of diseases on ALS patients. Moreover, patient-derived iPSCs are obtained from their own somatic cells, avoiding ethical concerns and posing only a low risk of immune rejection. The iPSC technology creates new hope for ALS treatment. Here, we review recent studies on iPSCs and their applications in disease modeling, drug screening and cell therapy in ALS, with a particular focus on the potential for ALS treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Hongmei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huo</LastName><ForeName>Zijun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yanchun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-4740-9228</Identifier><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Zhenhan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Fandi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-3527-2191</Identifier><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shiyue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Haoyun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Fenghua</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jinmeng</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6041-2723</Identifier><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lingyun</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3571-3209</Identifier><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Shuanhu</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4745-5347</Identifier><AffiliationInfo><Affiliation>Harvard Medical School and Harvard Stem Cell Institute, Harvard University, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Yingjun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9578-0497</Identifier><AffiliationInfo><Affiliation>Department of Histology and Embryology, School of Basic Medical Sciences, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurologic Disorders and Regenerative Repair Laboratory, Weifang Medical University, Weifang 261053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Harvard Medical School and Harvard Stem Cell Institute, Harvard University, Boston, MA 02115, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cell therapy</Keyword><Keyword MajorTopicYN="N">disease modeling</Keyword><Keyword MajorTopicYN="N">drug screening</Keyword><Keyword MajorTopicYN="N">induced pluripotent stem cells</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36980310</ArticleId><ArticleId IdType="pmc">PMC10047679</ArticleId><ArticleId IdType="doi">10.3390/cells12060971</ArticleId><ArticleId IdType="pii">cells12060971</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dafinca R., Scaber J., Ababneh N., Lalic T., Weir G., Christian H., Vowles J., Douglas A.G., Fletcher-Jones A., Browne C., et al. C9orf72 Hexanucleotide Expansions Are Associated with Altered Endoplasmic Reticulum Calcium Homeostasis and Stress Granule Formation in Induced Pluripotent Stem Cell-Derived Neurons from Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Stem Cells. 2016;34:2063&#x2013;2078.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979662</ArticleId><ArticleId IdType="pubmed">27097283</ArticleId></ArticleIdList></Reference><Reference><Citation>Pender N., Pinto-Grau M., Hardiman O. Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2020;33:649&#x2013;654. doi: 10.1097/WCO.0000000000000862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000862</ArticleId><ArticleId IdType="pubmed">32833751</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman E.L., Goutman S.A., Petri S., Mazzini L., Savelieff M.G., Shaw P.J., Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022;400:1363&#x2013;1380. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Liu T., Liu L., Yao X., Chen L., Fan D., Zhan S., Wang S. Global variation in prevalence and incidence of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. 2020;267:944&#x2013;953. doi: 10.1007/s00415-019-09652-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09652-y</ArticleId><ArticleId IdType="pubmed">31797084</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott E.O., Malek A., Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb. Clin. Neurol. 2016;138:225&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham J., Keon M., Brennan S., Saksena N. Connecting RNA-Modifying Similarities of TDP-43, FUS, and SOD1 with MicroRNA Dysregulation Amidst a Renewed Network Perspective of Amyotrophic Lateral Sclerosis Proteinopathy. Int. J. Mol. Sci. 2020;21:3464. doi: 10.3390/ijms21103464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21103464</ArticleId><ArticleId IdType="pmc">PMC7278980</ArticleId><ArticleId IdType="pubmed">32422969</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S., Kato M., Abe Y., Matsumura T., Nishino T., Aoki M., Itoyama Y., Asayama K., Awaya A., Hirano A., et al. Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): Immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Acta Neuropathol. 2005;110:101&#x2013;112. doi: 10.1007/s00401-005-1019-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1019-3</ArticleId><ArticleId IdType="pubmed">15983830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S.J., McKeown S., Rashid S. Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis. Gene. 2016;577:109&#x2013;118. doi: 10.1016/j.gene.2015.11.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.11.049</ArticleId><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J., Gomes C., de Carvalho M. Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis. CNS Neurol. Disord. Drug Targets. 2010;9:764&#x2013;778. doi: 10.2174/187152710793237502.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152710793237502</ArticleId><ArticleId IdType="pubmed">20942786</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten A.C.M., Phatnani H., Przedborski S. Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 2021;44:658&#x2013;668. doi: 10.1016/j.tins.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8972039</ArticleId><ArticleId IdType="pubmed">34006386</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P., Van Damme P. Amyotrophic lateral sclerosis: A clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Behl T., Kaur G., Sehgal A., Bhardwaj S., Singh S., Buhas C., Judea-Pusta C., Uivarosan D., Munteanu M.A., Bungau S. Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. Int. J. Mol. Sci. 2021;22:1413. doi: 10.3390/ijms22031413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22031413</ArticleId><ArticleId IdType="pmc">PMC7866808</ArticleId><ArticleId IdType="pubmed">33573368</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X. Potential role of gut microbiota and tissue barriers in Parkinson&#x2019;s disease and amyotrophic lateral sclerosis. Int. J. Neurosci. 2016;126:771&#x2013;776. doi: 10.3109/00207454.2015.1096271.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2015.1096271</ArticleId><ArticleId IdType="pubmed">26381230</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Q., Shen J., Chen K., Zhou J., Liao Q., Lu K., Yuan J., Bi F. The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. Sci. Rep. 2020;10:12998. doi: 10.1038/s41598-020-69845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-69845-8</ArticleId><ArticleId IdType="pmc">PMC7398913</ArticleId><ArticleId IdType="pubmed">32747678</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccolai E., Di Pilato V., Nannini G., Baldi S., Russo E., Zucchi E., Martinelli I., Menicatti M., Bartolucci G., Mandrioli J., et al. The Gut Microbiota-Immunity Axis in ALS: A Role in Deciphering Disease Heterogeneity? Biomedicines. 2021;9:753. doi: 10.3390/biomedicines9070753.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9070753</ArticleId><ArticleId IdType="pmc">PMC8301418</ArticleId><ArticleId IdType="pubmed">34209688</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K., Bjornevik K., Abu-Ali G., Chan J., Cortese M., Dedi B., Jeon M., Xavier R., Huttenhower C., Ascherio A., et al. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front. Degener. 2021;22:186&#x2013;194. doi: 10.1080/21678421.2020.1828475.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1828475</ArticleId><ArticleId IdType="pubmed">33135936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T., Camdessanche J. Amyotrophic lateral sclerosis or not: Keys for the diagnosis. Rev. Neurol. 2017;173:280&#x2013;287. doi: 10.1016/j.neurol.2017.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2017.04.003</ArticleId><ArticleId IdType="pubmed">28461025</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F., Zhu Y., Hsiao-Nakamoto J., Tang X., Dugas J.C., Moscovitch-Lopatin M., Glass J.D., Brown R.H., Jr., Ladha S.S., Lacomis D., et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2020;7:1103&#x2013;1116. doi: 10.1002/acn3.51078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S., Murn M., Choi P. Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest. 2019;155:401&#x2013;408. doi: 10.1016/j.chest.2018.06.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.06.035</ArticleId><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D. Edaravone: A new drug approved for ALS. Cell. 2017;171:725. doi: 10.1016/j.cell.2017.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2017.10.011</ArticleId><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S., Maier A., Steinbach R., Grosskreutz J., Koch J.C., Sarikidi A., Petri S., Gunther R., Wolf J., Hermann A., et al. Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients with Amyotrophic Lateral Sclerosis. JAMA Neurol. 2022;79:121&#x2013;130. doi: 10.1001/jamaneurol.2021.4893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId><ArticleId IdType="pmc">PMC8749709</ArticleId><ArticleId IdType="pubmed">35006266</ArticleId></ArticleIdList></Reference><Reference><Citation>Aschenbrenner D.S. New Drug Approved For ALS. Am. J. Nurs. 2023;123:22&#x2013;23. doi: 10.1097/01.NAJ.0000911516.31267.67.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.NAJ.0000911516.31267.67</ArticleId><ArticleId IdType="pubmed">36546382</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T.M., Cudkowicz M.E., Genge A., Shaw P.J., Sobue G., Bucelli R.C., Chio A., Van Damme P., Ludolph A.C., Glass J.D., et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663&#x2013;676. doi: 10.1016/j.cell.2006.07.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.07.024</ArticleId><ArticleId IdType="pubmed">16904174</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872. doi: 10.1016/j.cell.2007.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.11.019</ArticleId><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimos J.T., Rodolfa K.T., Niakan K.K., Weisenthal L.M., Mitsumoto H., Chung W., Croft G.F., Saphier G., Leibel R., Goland R., et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321:1218&#x2013;1221. doi: 10.1126/science.1158799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1158799</ArticleId><ArticleId IdType="pubmed">18669821</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Maragakis N. Mini-Review: Induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neurosci. Lett. 2021;755:135911. doi: 10.1016/j.neulet.2021.135911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135911</ArticleId><ArticleId IdType="pubmed">33892003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray A., Joshi J.M., Sundaravadivelu P.K., Raina K., Lenka N., Kaveeshwar V., Thummer R.P. An Overview on Promising Somatic Cell Sources Utilized for the Efficient Generation of Induced Pluripotent Stem Cells. Stem Cell Rev. Rep. 2021;17:1954&#x2013;1974. doi: 10.1007/s12015-021-10200-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-021-10200-3</ArticleId><ArticleId IdType="pubmed">34100193</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M., Koyanagi M., Tanabe K., Takahashi K., Ichisaka T., Aoi T., Okita K., Mochiduki Y., Takizawa N., Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat. Biotechnol. 2008;26:101&#x2013;106. doi: 10.1038/nbt1374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1374</ArticleId><ArticleId IdType="pubmed">18059259</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W., Freed C. Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells. 2009;27:2667&#x2013;2674. doi: 10.1002/stem.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.201</ArticleId><ArticleId IdType="pubmed">19697349</ArticleId></ArticleIdList></Reference><Reference><Citation>Haase A., Olmer R., Schwanke K., Wunderlich S., Merkert S., Hess C., Zweigerdt R., Gruh I., Meyer J., Wagner S., et al. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell. 2009;5:434&#x2013;441. doi: 10.1016/j.stem.2009.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2009.08.021</ArticleId><ArticleId IdType="pubmed">19796623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D., Kim C.H., Moon J.I., Chung Y.G., Chang M.Y., Han B.S., Ko S., Yang E., Cha K.Y., Lanza R., et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472&#x2013;476. doi: 10.1016/j.stem.2009.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2009.05.005</ArticleId><ArticleId IdType="pmc">PMC2705327</ArticleId><ArticleId IdType="pubmed">19481515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakubov E., Rechavi G., Rozenblatt S., Givol D. Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem. Biophys. Res. Commun. 2010;394:189&#x2013;193. doi: 10.1016/j.bbrc.2010.02.150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2010.02.150</ArticleId><ArticleId IdType="pubmed">20188704</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusaki N., Ban H., Nishiyama A., Saeki K., Hasegawa M. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009;85:348&#x2013;362. doi: 10.2183/pjab.85.348.</Citation><ArticleIdList><ArticleId IdType="doi">10.2183/pjab.85.348</ArticleId><ArticleId IdType="pmc">PMC3621571</ArticleId><ArticleId IdType="pubmed">19838014</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Zhu J., Dai Y., Wang L., Liu R., Guo X. Generation of an induced pluripotent stem cell line (ZZUi034-A) from a 65 year old Chinese female donor with sendai virus reprogramming protocol. Stem Cell Res. 2022;62:102788. doi: 10.1016/j.scr.2022.102788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2022.102788</ArticleId><ArticleId IdType="pubmed">35462158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou P., Li Y., Zhang X., Liu C., Guan J., Li H., Zhao T., Ye J., Yang W., Liu K., et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341:651&#x2013;654. doi: 10.1126/science.1239278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1239278</ArticleId><ArticleId IdType="pubmed">23868920</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Long Q., Wang T., Zhao D., Zhou Y., Qi J., Wu Y., Li S., Chen C., Zeng X., et al. Gadd45a is a heterochromatin relaxer that enhances iPS cell generation. EMBO Rep. 2016;17:1641&#x2013;1656. doi: 10.15252/embr.201642402.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201642402</ArticleId><ArticleId IdType="pmc">PMC5090707</ArticleId><ArticleId IdType="pubmed">27702986</ArticleId></ArticleIdList></Reference><Reference><Citation>Haraguchi D., Nakamura T. Pramef12 enhances reprogramming into naive iPS cells. Biochem. Biophys. Rep. 2022;30:101267. doi: 10.1016/j.bbrep.2022.101267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrep.2022.101267</ArticleId><ArticleId IdType="pmc">PMC9111934</ArticleId><ArticleId IdType="pubmed">35592616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S., Huang E. Modeling ALS and FTD with iPSC-derived neurons. Brain Res. 2017;1656:88&#x2013;97. doi: 10.1016/j.brainres.2015.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.10.003</ArticleId><ArticleId IdType="pmc">PMC4833714</ArticleId><ArticleId IdType="pubmed">26462653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamas N.J., Roybon L. Harnessing the Potential of Human Pluripotent Stem Cell-Derived Motor Neurons for Drug Discovery in Amyotrophic Lateral Sclerosis: From the Clinic to the Laboratory and Back to the Patient. Front. Drug Discov. 2021;1:773424. doi: 10.3389/fddsv.2021.773424.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fddsv.2021.773424</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo Bautista C.M., Sterneckert J. Progress and challenges in directing the differentiation of human iPSCs into spinal motor neurons. Front. Cell Dev. Biol. 2022;10:1089970. doi: 10.3389/fcell.2022.1089970.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.1089970</ArticleId><ArticleId IdType="pmc">PMC9849822</ArticleId><ArticleId IdType="pubmed">36684437</ArticleId></ArticleIdList></Reference><Reference><Citation>Son E.Y., Ichida J.K., Wainger B.J., Toma J.S., Rafuse V.F., Woolf C.J., Eggan K. Conversion of mouse and human fibroblasts into functional spinal motor neurons. Cell Stem Cell. 2011;9:205&#x2013;218. doi: 10.1016/j.stem.2011.07.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2011.07.014</ArticleId><ArticleId IdType="pmc">PMC3188987</ArticleId><ArticleId IdType="pubmed">21852222</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronchi S., Buccino A.P., Prack G., Kumar S.S., Schroter M., Fiscella M., Hierlemann A. Electrophysiological Phenotype Characterization of Human iPSC-Derived Neuronal Cell Lines by Means of High-Density Microelectrode Arrays. Adv. Biol. 2021;5:e2000223. doi: 10.1002/adbi.202000223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/adbi.202000223</ArticleId><ArticleId IdType="pmc">PMC7610355</ArticleId><ArticleId IdType="pubmed">33729694</ArticleId></ArticleIdList></Reference><Reference><Citation>Toma J.S., Shettar B.C., Chipman P.H., Pinto D.M., Borowska J.P., Ichida J.K., Fawcett J.P., Zhang Y., Eggan K., Rafuse V.F. Motoneurons derived from induced pluripotent stem cells develop mature phenotypes typical of endogenous spinal motoneurons. J. Neurosci. 2015;35:1291&#x2013;1306. doi: 10.1523/JNEUROSCI.2126-14.2015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2126-14.2015</ArticleId><ArticleId IdType="pmc">PMC4402330</ArticleId><ArticleId IdType="pubmed">25609642</ArticleId></ArticleIdList></Reference><Reference><Citation>Azadmanesh J., Borgstahl G. A Review of the Catalytic Mechanism of Human Manganese Superoxide Dismutase. Antioxidants. 2018;7:25. doi: 10.3390/antiox7020025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox7020025</ArticleId><ArticleId IdType="pmc">PMC5836015</ArticleId><ArticleId IdType="pubmed">29385710</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Qian K., Du Z., Cao J., Petersen A., Liu H., Blackbourn L.W.t., Huang C.L., Errigo A., Yin Y., et al. Modeling ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor neurons. Cell Stem Cell. 2014;14:796&#x2013;809. doi: 10.1016/j.stem.2014.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.02.004</ArticleId><ArticleId IdType="pmc">PMC4230530</ArticleId><ArticleId IdType="pubmed">24704493</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiskinis E., Sandoe J., Williams L.A., Boulting G.L., Moccia R., Wainger B.J., Han S., Peng T., Thams S., Mikkilineni S., et al. Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. Cell Stem Cell. 2014;14:781&#x2013;795. doi: 10.1016/j.stem.2014.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2014.03.004</ArticleId><ArticleId IdType="pmc">PMC4653065</ArticleId><ArticleId IdType="pubmed">24704492</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Watanabe A., Tsukita K., Woltjen K., Yamamoto T., Hotta A., Kondo T., Kitaoka S., Ohta A., et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaaf3962. doi: 10.1126/scitranslmed.aaf3962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C.J., Zhang P.W., Pham J.T., Haeusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S., Gascon E., Tran H., Chou H.J., Gendron T.F., Degroot S., Tapper A.R., Sellier C., Charlet-Berguerand N., Karydas A., et al. Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013;126:385&#x2013;399. doi: 10.1007/s00401-013-1149-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1149-y</ArticleId><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T., McAvoy K., Russell K., Wen X., Pang Y., Morris B., Pasinelli P., Trotti D., Haeusler A. Repeat-associated non-AUG translation in C9orf72-ALS/FTD is driven by neuronal excitation and stress. EMBO Mol. Med. 2019;11:e9423. doi: 10.15252/emmm.201809423.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201809423</ArticleId><ArticleId IdType="pmc">PMC6365928</ArticleId><ArticleId IdType="pubmed">30617154</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakae N., Bieniek K.F., Zhang Y.J., Ross K., Gendron T.F., Murray M.E., Rademakers R., Petrucelli L., Dickson D.W. Poly-GR dipeptide repeat polymers correlate with neurodegeneration and Clinicopathological subtypes in C9ORF72-related brain disease. Acta Neuropathol. Commun. 2018;6:63. doi: 10.1186/s40478-018-0564-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0564-7</ArticleId><ArticleId IdType="pmc">PMC6054740</ArticleId><ArticleId IdType="pubmed">30029693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R., Lu Y., Gendron T.F., Karydas A., Tran H., Yang D., Petrucelli L., Miller B.L., Almeida S., Gao F.B. Poly(GR) in C9ORF72-Related ALS/FTD Compromises Mitochondrial Function and Increases Oxidative Stress and DNA Damage in iPSC-Derived Motor Neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.H., Badders N., Valentine M., Miller B.L., Wong P.C., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133. doi: 10.1038/nature14974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14974</ArticleId><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Barbagallo P., Farrimond L., Candalija A., Scaber J., Ababneh N.A., Sathyaprakash C., Vowles J., Cowley S.A., Talbot K. Impairment of Mitochondrial Calcium Buffering Links Mutations in C9ORF72 and TARDBP in iPS-Derived Motor Neurons from Patients with ALS/FTD. Stem Cell Rep. 2020;14:892&#x2013;908. doi: 10.1016/j.stemcr.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Suaga P., Morotz G.M., Markovinovic A., Martin-Guerrero S.M., Preza E., Arias N., Mayl K., Aabdien A., Gesheva V., Nishimura A., et al. Disruption of ER-mitochondria tethering and signalling in C9orf72-associated amyotrophic lateral sclerosis and frontotemporal dementia. Aging Cell. 2022;21:e13549. doi: 10.1111/acel.13549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13549</ArticleId><ArticleId IdType="pmc">PMC8844122</ArticleId><ArticleId IdType="pubmed">35026048</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro L.C., Li J., Lim R.G., Kaye J.A., Dardov V., Coyne A.N., Wu J., Milani P., Cheng A., Thompson T.G., et al. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients. iScience. 2021;24:103221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554488</ArticleId><ArticleId IdType="pubmed">34746695</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B., Serio A., Barmada S.J., Nishimura A.L., Sullivan G.J., Carrasco M., Phatnani H.P., Puddifoot C.A., Story D., Fletcher J., et al. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc. Natl. Acad. Sci. USA. 2012;109:5803&#x2013;5808. doi: 10.1073/pnas.1202922109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202922109</ArticleId><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>Egawa N., Kitaoka S., Tsukita K., Naitoh M., Takahashi K., Yamamoto T., Adachi F., Kondo T., Okita K., Asaka I., et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci. Transl. Med. 2012;4:145ra104. doi: 10.1126/scitranslmed.3004052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3004052</ArticleId><ArticleId IdType="pubmed">22855461</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiter N., Pal A., Lojewski X., Corcia P., Naujock M., Reinhardt P., Sterneckert J., Petri S., Wegner F., Storch A., et al. Age-dependent neurodegeneration and organelle transport deficiencies in mutant TDP43 patient-derived neurons are independent of TDP43 aggregation. Neurobiol. Dis. 2018;115:167&#x2013;181. doi: 10.1016/j.nbd.2018.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.03.010</ArticleId><ArticleId IdType="pubmed">29630989</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.H., Davidson S., Harapas C.R., Hilton J.B., Mlodzianoski M.J., Laohamonthonkul P., Louis C., Low R.R.J., Moecking J., De Nardo D., et al. TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649 e18. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J., Demestre M., Putz S., Delling J.P., Jacob C., Lutz A.K., Bausinger J., Huber A.K., Klingenstein M., Barbi G., et al. FUS Mislocalization and Vulnerability to DNA Damage in ALS Patients Derived hiPSCs and Aging Motoneurons. Front. Cell Neurosci. 2016;10:290. doi: 10.3389/fncel.2016.00290.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2016.00290</ArticleId><ArticleId IdType="pmc">PMC5183648</ArticleId><ArticleId IdType="pubmed">28082870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M., Hutten S., Bourgeois B., Spreitzer E., Niedner-Boblenz A., Schifferer M., Ruepp M.D., Simons M., Niessing D., Madl T., et al. Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation. Cell. 2018;173:706&#x2013;719.e13. doi: 10.1016/j.cell.2018.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.004</ArticleId><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Reber S., Jutzi D., Lindsay H., Devoy A., Mechtersheimer J., Levone B.R., Domanski M., Bentmann E., Dormann D., Muhlemann O., et al. The phase separation-dependent FUS interactome reveals nuclear and cytoplasmic function of liquid-liquid phase separation. Nucleic Acids Res. 2021;49:7713&#x2013;7731. doi: 10.1093/nar/gkab582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab582</ArticleId><ArticleId IdType="pmc">PMC8287939</ArticleId><ArticleId IdType="pubmed">34233002</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Chen J., Liu W., Li X., Chen Q., Liu T., Gao S., Deng M. The fused in sarcoma protein forms cytoplasmic aggregates in motor neurons derived from integration-free induced pluripotent stem cells generated from a patient with familial amyotrophic lateral sclerosis carrying the FUS-P525L mutation. Neurogenetics. 2015;16:223&#x2013;231. doi: 10.1007/s10048-015-0448-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10048-015-0448-y</ArticleId><ArticleId IdType="pubmed">25912081</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L., Poser I., Casci I., Japtok J., Reinhardt P., Janosch A., Andree C., Lee H.O., Moebius C., Koerner E., et al. Isogenic FUS-eGFP iPSC Reporter Lines Enable Quantification of FUS Stress Granule Pathology that Is Rescued by Drugs Inducing Autophagy. Stem Cell Rep. 2018;10:375&#x2013;389. doi: 10.1016/j.stemcr.2017.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2017.12.018</ArticleId><ArticleId IdType="pmc">PMC5857889</ArticleId><ArticleId IdType="pubmed">29358088</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Naujock M., Fumagalli L., Vandoorne T., Baatsen P., Boon R., Ordovas L., Patel A., Welters M., Vanwelden T., et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Picchiarelli G., Demestre M., Zuko A., Been M., Higelin J., Dieterle S., Goy M.A., Mallik M., Sellier C., Scekic-Zahirovic J., et al. FUS-mediated regulation of acetylcholine receptor transcription at neuromuscular junctions is compromised in amyotrophic lateral sclerosis. Nat. Neurosci. 2019;22:1793&#x2013;1805. doi: 10.1038/s41593-019-0498-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0498-9</ArticleId><ArticleId IdType="pmc">PMC6858880</ArticleId><ArticleId IdType="pubmed">31591561</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y.L., Mu Y., Manley J. Nuclear RNA transcript levels modulate nucleocytoplasmic distribution of ALS/FTD-associated protein FUS. Sci. Rep. 2022;12:8180. doi: 10.1038/s41598-022-12098-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-12098-4</ArticleId><ArticleId IdType="pmc">PMC9114323</ArticleId><ArticleId IdType="pubmed">35581240</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubert F., Vasques J.F., Cozendey T.D., Domizi P., Toledo M.F., Kasai-Brunswick T.H., Loureiro M.P.S., Lima J.M.B., Gress C.H., Cabello G.M.K., et al. Generation of four patient-specific pluripotent induced stem cell lines from two Brazilian patients with amyotrophic lateral sclerosis and two healthy subjects. Stem Cell Res. 2019;37:101448. doi: 10.1016/j.scr.2019.101448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2019.101448</ArticleId><ArticleId IdType="pubmed">31077962</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt M.F., Martinez F.J., Wright S., Ramos C., Volfson D., Mason M., Garnes J., Dang V., Lievers J., Shoukat-Mumtaz U., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell Neurosci. 2013;56:355&#x2013;364. doi: 10.1016/j.mcn.2013.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.07.007</ArticleId><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Alves C.J., Dariolli R., Jorge F.M., Monteiro M.R., Maximino J.R., Martins R.S., Strauss B.E., Krieger J.E., Callegaro D., Chadi G. Gene expression profiling for human iPS-derived motor neurons from sporadic ALS patients reveals a strong association between mitochondrial functions and neurodegeneration. Front. Cell Neurosci. 2015;9:289. doi: 10.3389/fncel.2015.00289.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2015.00289</ArticleId><ArticleId IdType="pmc">PMC4523944</ArticleId><ArticleId IdType="pubmed">26300727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Song J., Huang H., Chen H., Qian K. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells. Stem Cell Res. Ther. 2018;9:315. doi: 10.1186/s13287-018-1048-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-018-1048-1</ArticleId><ArticleId IdType="pmc">PMC6238404</ArticleId><ArticleId IdType="pubmed">30442180</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxi E.G., Thompson T., Li J., Kaye J.A., Lim R.G., Wu J., Ramamoorthy D., Lima L., Vaibhav V., Matlock A., et al. Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines. Nat. Neurosci. 2022;25:226&#x2013;237. doi: 10.1038/s41593-021-01006-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-01006-0</ArticleId><ArticleId IdType="pmc">PMC8825283</ArticleId><ArticleId IdType="pubmed">35115730</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Kiskinis E., Mellin C., Wiskow O., Han S.S., Sandoe J., Perez N.P., Williams L.A., Lee S., Boulting G., et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1&#x2013;11. doi: 10.1016/j.celrep.2014.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.019</ArticleId><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bristol L.A., Rothstein J. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann. Neurol. 1996;39:676&#x2013;679. doi: 10.1002/ana.410390519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410390519</ArticleId><ArticleId IdType="pubmed">8619555</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack G., Lakatos A., Patani R. Human Stem Cell-Derived Astrocytes: Specification and Relevance for Neurological Disorders. Curr. Stem Cell Rep. 2016;2:236&#x2013;247. doi: 10.1007/s40778-016-0049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40778-016-0049-1</ArticleId><ArticleId IdType="pmc">PMC4972864</ArticleId><ArticleId IdType="pubmed">27547709</ArticleId></ArticleIdList></Reference><Reference><Citation>Muffat J., Li Y., Yuan B., Mitalipova M., Omer A., Corcoran S., Bakiasi G., Tsai L.H., Aubourg P., Ransohoff R.M., et al. Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat. Med. 2016;22:1358&#x2013;1367. doi: 10.1038/nm.4189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4189</ArticleId><ArticleId IdType="pmc">PMC5101156</ArticleId><ArticleId IdType="pubmed">27668937</ArticleId></ArticleIdList></Reference><Reference><Citation>Madill M., McDonagh K., Ma J., Vajda A., McLoughlin P., O&#x2019;Brien T., Hardiman O., Shen S. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol. Brain. 2017;10:22. doi: 10.1186/s13041-017-0300-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0300-4</ArticleId><ArticleId IdType="pmc">PMC5470320</ArticleId><ArticleId IdType="pubmed">28610619</ArticleId></ArticleIdList></Reference><Reference><Citation>Birger A., Ben-Dor I., Ottolenghi M., Turetsky T., Gil Y., Sweetat S., Perez L., Belzer V., Casden N., Steiner D., et al. Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity. EBioMedicine. 2019;50:274&#x2013;289. doi: 10.1016/j.ebiom.2019.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2019.11.026</ArticleId><ArticleId IdType="pmc">PMC6921360</ArticleId><ArticleId IdType="pubmed">31787569</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Devlin A.C., Chouhan A.K., Selvaraj B.T., Stavrou M., Burr K., Brivio V., He X., Mehta A.R., Story D., et al. Mutant C9orf72 human iPSC-derived astrocytes cause non-cell autonomous motor neuron pathophysiology. Glia. 2020;68:1046&#x2013;1064. doi: 10.1002/glia.23761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23761</ArticleId><ArticleId IdType="pmc">PMC7078830</ArticleId><ArticleId IdType="pubmed">31841614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajpurohit C.S., Kumar V., Cheffer A., Oliveira D., Ulrich H., Okamoto O.K., Zatz M., Ansari U.A., Khanna V.K., Pant A.B. Mechanistic Insights of Astrocyte-Mediated Hyperactive Autophagy and Loss of Motor Neuron Function in SOD1(L39R) Linked Amyotrophic Lateral Sclerosis. Mol. Neurobiol. 2020;57:4117&#x2013;4133. doi: 10.1007/s12035-020-02006-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-020-02006-0</ArticleId><ArticleId IdType="pubmed">32676988</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng B., Amponsah A.E., Guo R., Liu X., Zhang J., Du X., Zhou Z., He J., Ma J., Cui H. Autophagy-Mediated Inflammatory Cytokine Secretion in Sporadic ALS Patient iPSC-Derived Astrocytes. Oxid. Med. Cell Longev. 2022;2022:6483582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9423978</ArticleId><ArticleId IdType="pubmed">36046683</ArticleId></ArticleIdList></Reference><Reference><Citation>Allison R.L., Adelman J.W., Abrudan J., Urrutia R.A., Zimmermann M.T., Mathison A.J., Ebert A.D. Microglia Influence Neurofilament Deposition in ALS iPSC-Derived Motor Neurons. Genes. 2022;13:241. doi: 10.3390/genes13020241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13020241</ArticleId><ArticleId IdType="pmc">PMC8871895</ArticleId><ArticleId IdType="pubmed">35205286</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerk S.Y., Bai Y., Smith J., Lalgudi P., Hunt C., Kuno J., Nuara J., Yang T., Lanza K., Chan N., et al. Homozygous ALS-linked FUS P525L mutations cell-autonomously perturb transcriptome profile and chemoreceptor signaling in human iPSC microglia. Stem Cell Rep. 2022;17:678&#x2013;692. doi: 10.1016/j.stemcr.2022.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2022.01.004</ArticleId><ArticleId IdType="pmc">PMC9039753</ArticleId><ArticleId IdType="pubmed">35120624</ArticleId></ArticleIdList></Reference><Reference><Citation>Eitan C., Siany A., Barkan E., Olender T., van Eijk K.R., Moisse M., Farhan S.M.K., Danino Y.M., Yanowski E., Marmor-Kollet H., et al. Whole-genome sequencing reveals that variants in the Interleukin 18 Receptor Accessory Protein 3&#x2019;UTR protect against ALS. Nat. Neurosci. 2022;25:433&#x2013;445. doi: 10.1038/s41593-022-01040-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-022-01040-6</ArticleId><ArticleId IdType="pubmed">35361972</ArticleId></ArticleIdList></Reference><Reference><Citation>Barres B.A. The mystery and magic of glia: A perspective on their roles in health and disease. Neuron. 2008;60:430&#x2013;440. doi: 10.1016/j.neuron.2008.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.10.013</ArticleId><ArticleId IdType="pubmed">18995817</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow S.A., Guttenplan K.A., Clarke L.E., Bennett F.C., Bohlen C.J., Schirmer L., Bennett M.L., Munch A.E., Chung W.S., Peterson T.C., et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481&#x2013;487. doi: 10.1038/nature21029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature21029</ArticleId><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrige M., Frank E., Herardot E., Martineau S., Darle A., Benabides M., Domingues S., Chose O., Habeler W., Lorant J., et al. The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles. Cells. 2021;10:240. doi: 10.3390/cells10020240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020240</ArticleId><ArticleId IdType="pmc">PMC7912181</ArticleId><ArticleId IdType="pubmed">33513719</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science. 2003;302:113&#x2013;117. doi: 10.1126/science.1086071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1086071</ArticleId><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M., Keyhanian K., Douthwright C. Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Cells. 2021;10:249. doi: 10.3390/cells10020249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020249</ArticleId><ArticleId IdType="pmc">PMC7912327</ArticleId><ArticleId IdType="pubmed">33525344</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D., Gowing G., Sahabian A., Staggenborg K., Paradis R., Avalos P., Latter J., Ornelas L., Garcia L., Svendsen C.N. Human induced pluripotent stem cells are a novel source of neural progenitor cells (iNPCs) that migrate and integrate in the rodent spinal cord. J. Comp. Neurol. 2014;522:2707&#x2013;2728. doi: 10.1002/cne.23578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.23578</ArticleId><ArticleId IdType="pmc">PMC4070510</ArticleId><ArticleId IdType="pubmed">24610630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T., Funayama M., Tsukita K., Hotta A., Yasuda A., Nori S., Kaneko S., Nakamura M., Takahashi R., Okano H., et al. Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem Cell Rep. 2014;3:242&#x2013;249. doi: 10.1016/j.stemcr.2014.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2014.05.017</ArticleId><ArticleId IdType="pmc">PMC4175543</ArticleId><ArticleId IdType="pubmed">25254338</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu I.R., Nicaise C., Liu S., Bisch G., Knippenberg S., Daubie V., Bohl D., Pochet R. Neural progenitors derived from human induced pluripotent stem cells survive and differentiate upon transplantation into a rat model of amyotrophic lateral sclerosis. Stem Cells Transl. Med. 2013;2:167&#x2013;174. doi: 10.5966/sctm.2012-0042.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2012-0042</ArticleId><ArticleId IdType="pmc">PMC3659761</ArticleId><ArticleId IdType="pubmed">23413376</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzardo M., Simone C., Rizzo F., Ruggieri M., Salani S., Riboldi G., Faravelli I., Zanetta C., Bresolin N., Comi G.P., et al. Minimally invasive transplantation of iPSC-derived ALDHhiSSCloVLA4+ neural stem cells effectively improves the phenotype of an amyotrophic lateral sclerosis model. Hum. Mol. Genet. 2014;23:342&#x2013;354. doi: 10.1093/hmg/ddt425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt425</ArticleId><ArticleId IdType="pmc">PMC3869354</ArticleId><ArticleId IdType="pubmed">24006477</ArticleId></ArticleIdList></Reference><Reference><Citation>Nizzardo M., Bucchia M., Ramirez A., Trombetta E., Bresolin N., Comi G.P., Corti S. iPSC-derived LewisX+CXCR4+beta1-integrin+ neural stem cells improve the amyotrophic lateral sclerosis phenotype by preserving motor neurons and muscle innervation in human and rodent models. Hum. Mol. Genet. 2016;25:3152&#x2013;3163. doi: 10.1093/hmg/ddw163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddw163</ArticleId><ArticleId IdType="pubmed">27270413</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosati J., Ferrari D., Altieri F., Tardivo S., Ricciolini C., Fusilli C., Zalfa C., Profico D.C., Pinos F., Bernardini L., et al. Establishment of stable iPS-derived human neural stem cell lines suitable for cell therapies. Cell Death Dis. 2018;9:937. doi: 10.1038/s41419-018-0990-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0990-2</ArticleId><ArticleId IdType="pmc">PMC6141489</ArticleId><ArticleId IdType="pubmed">30224709</ArticleId></ArticleIdList></Reference><Reference><Citation>Forostyak S., Forostyak O., Kwok J.C.F., Romanyuk N., Rehorova M., Kriska J., Dayanithi G., Raha-Chowdhury R., Jendelova P., Anderova M., et al. Transplantation of Neural Precursors Derived from Induced Pluripotent Cells Preserve Perineuronal Nets and Stimulate Neural Plasticity in ALS Rats. Int. J. Mol. Sci. 2020;21:9593. doi: 10.3390/ijms21249593.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21249593</ArticleId><ArticleId IdType="pmc">PMC7766921</ArticleId><ArticleId IdType="pubmed">33339362</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Li M., Zhang L., Chen Z., Lu P. Motor neuron replacement therapy for amyotrophic lateral sclerosis. Neural Regen. Res. 2022;17:1633&#x2013;1639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820706</ArticleId><ArticleId IdType="pubmed">35017408</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Feng L., Liang L., Stacey G.N., Wang C., Wang Y., Hu B. Neuronal cell-based medicines from pluripotent stem cells: Development, production, and preclinical assessment. Stem Cells Transl. Med. 2021;10:S31&#x2013;S40. doi: 10.1002/sctm.20-0522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.20-0522</ArticleId><ArticleId IdType="pmc">PMC8560198</ArticleId><ArticleId IdType="pubmed">34724724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting H.C., Su H.L., Chen M.F., Harn H.J., Lin S.Z., Chiou T.W., Chang C.Y. Robust Generation of Ready-to-Use Cryopreserved Motor Neurons from Human Pluripotent Stem Cells for Disease Modeling. Int. J. Mol. Sci. 2022;23:13462. doi: 10.3390/ijms232113462.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232113462</ArticleId><ArticleId IdType="pmc">PMC9657726</ArticleId><ArticleId IdType="pubmed">36362259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y., Ohnuma K., Furue M. Pluripotent Stem Cell Heterogeneity. Adv. Exp. Med. Biol. 2019;1123:71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">31016596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar S., Benvenisty N. Epigenetic aberrations in human pluripotent stem cells. EMBO J. 2019;38:e101033. doi: 10.15252/embj.2018101033.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2018101033</ArticleId><ArticleId IdType="pmc">PMC6576196</ArticleId><ArticleId IdType="pubmed">31088843</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacomelli E., Vahsen B.F., Calder E.L., Xu Y., Scaber J., Gray E., Dafinca R., Talbot K., Studer L. Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation. Cell Stem Cell. 2022;29:11&#x2013;35. doi: 10.1016/j.stem.2021.12.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2021.12.008</ArticleId><ArticleId IdType="pmc">PMC8785905</ArticleId><ArticleId IdType="pubmed">34995492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnuki M., Takahashi K. Present and future challenges of induced pluripotent stem cells. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2015;370:20140367. doi: 10.1098/rstb.2014.0367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2014.0367</ArticleId><ArticleId IdType="pmc">PMC4633996</ArticleId><ArticleId IdType="pubmed">26416678</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H., Yasuda D., Fujimori K., Morimoto S., Takahashi S. Ropinirole, a New ALS Drug Candidate Developed Using iPSCs. Trends Pharmacol. Sci. 2020;41:99&#x2013;109. doi: 10.1016/j.tips.2019.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuburaya N., Homma K., Higuchi T., Balia A., Yamakoshi H., Shibata N., Nakamura S., Nakagawa H., Ikeda S.I., Umezawa N., et al. A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model. Nat. Commun. 2018;9:2668. doi: 10.1038/s41467-018-05127-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-05127-2</ArticleId><ArticleId IdType="pmc">PMC6039432</ArticleId><ArticleId IdType="pubmed">29991716</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang M.Y., Markmiller S., Vu A.Q., Javaherian A., Dowdle W.E., Jolivet P., Bushway P.J., Castello N.A., Baral A., Chan M.Y., et al. Small-Molecule Modulation of TDP-43 Recruitment to Stress Granules Prevents Persistent TDP-43 Accumulation in ALS/FTD. Neuron. 2019;103:802&#x2013;819.e11. doi: 10.1016/j.neuron.2019.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.05.048</ArticleId><ArticleId IdType="pmc">PMC6728177</ArticleId><ArticleId IdType="pubmed">31272829</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuta R., Larochelle N., Fernandez M., Pal A., Minotti S., Tibshirani M., St Louis K., Gentil B.J., Nalbantoglu J.N., Hermann A., et al. Depending on the stress, histone deacetylase inhibitors act as heat shock protein co-inducers in motor neurons and potentiate arimoclomol, exerting neuroprotection through multiple mechanisms in ALS models. Cell Stress Chaperones. 2020;25:173&#x2013;191. doi: 10.1007/s12192-019-01064-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12192-019-01064-1</ArticleId><ArticleId IdType="pmc">PMC6985055</ArticleId><ArticleId IdType="pubmed">31900865</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y., Sakamoto K. Niclosamide affects intracellular TDP-43 distribution in motor neurons, activates mitophagy, and attenuates morphological changes under stress. J. Biosci. Bioeng. 2021;132:640&#x2013;650. doi: 10.1016/j.jbiosc.2021.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiosc.2021.06.015</ArticleId><ArticleId IdType="pubmed">34429248</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Banno H., Uozumi R., Morita S., Egawa N., Ayaki T., Nagai M., Nishiyama K., Watanabe Y., et al. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: Protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients. BMJ Open. 2019;9:e033131. doi: 10.1136/bmjopen-2019-033131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-033131</ArticleId><ArticleId IdType="pmc">PMC7003406</ArticleId><ArticleId IdType="pubmed">31796494</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Izumi Y., Nagai M., Nishiyama K., Watanabe Y., Hanajima R., Egawa N., Ayaki T., Oki R., Fujita K., et al. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial. EClinicalMedicine. 2022;53:101707. doi: 10.1016/j.eclinm.2022.101707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101707</ArticleId><ArticleId IdType="pmc">PMC9716331</ArticleId><ArticleId IdType="pubmed">36467452</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S., Takahashi S., Fukushima K., Saya H., Suzuki N., Aoki M., Okano H., Nakahara J. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis&#x2014;Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial) Regen. Ther. 2019;11:143&#x2013;166. doi: 10.1016/j.reth.2019.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reth.2019.07.002</ArticleId><ArticleId IdType="pmc">PMC6661418</ArticleId><ArticleId IdType="pubmed">31384636</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleutjes B., Stikvoort Garcia D.J.L., Kovalchuk M.O., Heuberger J., Groeneveld G.J., Franssen H., van den Berg L.H. Acute retigabine-induced effects on myelinated motor axons in amyotrophic lateral sclerosis. Pharmacol. Res. Perspect. 2022;10:e00983. doi: 10.1002/prp2.983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prp2.983</ArticleId><ArticleId IdType="pmc">PMC9318643</ArticleId><ArticleId IdType="pubmed">35881020</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Macklin E.A., Vucic S., McIlduff C.E., Paganoni S., Maragakis N.J., Bedlack R., Goyal N.A., Rutkove S.B., Lange D.J., et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021;78:186&#x2013;196. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.Y., Lee J.H., Chung A.Y., Jo Y., Shin J.H., Park H.C., Kim H., Lopez-Gonzalez R., Ryu J.R., Sun W. Prevention of mitochondrial impairment by inhibition of protein phosphatase 1 activity in amyotrophic lateral sclerosis. Cell Death Dis. 2020;11:888. doi: 10.1038/s41419-020-03102-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03102-8</ArticleId><ArticleId IdType="pmc">PMC7578657</ArticleId><ArticleId IdType="pubmed">33087694</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jongh R., Spijkers X.M., Pasteuning-Vuhman S., Vulto P., Pasterkamp R.J. Neuromuscular junction-on-a-chip: ALS disease modeling and read-out development in microfluidic devices. J. Neurochem. 2021;157:393&#x2013;412. doi: 10.1111/jnc.15289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15289</ArticleId><ArticleId IdType="pubmed">33382092</ArticleId></ArticleIdList></Reference><Reference><Citation>Namboori S.C., Thomas P., Ames R., Hawkins S., Garrett L.O., Willis C.R.G., Rosa A., Stanton L.W., Bhinge A. Single-cell transcriptomics identifies master regulators of neurodegeneration in SOD1 ALS iPSC-derived motor neurons. Stem Cell Rep. 2021;16:3020&#x2013;3035. doi: 10.1016/j.stemcr.2021.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.10.010</ArticleId><ArticleId IdType="pmc">PMC8693652</ArticleId><ArticleId IdType="pubmed">34767750</ArticleId></ArticleIdList></Reference><Reference><Citation>Deneault E., Chaineau M., Nicouleau M., Castellanos Montiel M.J., Franco Flores A.K., Haghi G., Chen C.X., Abdian N., Shlaifer I., Beitel L.K., et al. A streamlined CRISPR workflow to introduce mutations and generate isogenic iPSCs for modeling amyotrophic lateral sclerosis. Methods. 2022;203:297&#x2013;310. doi: 10.1016/j.ymeth.2021.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymeth.2021.09.002</ArticleId><ArticleId IdType="pubmed">34500068</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K., Yada Y., Izumi Y., Morita M., Kawata A., Arisato T., Nagahashi A., Enami T., Tsukita K., Kawakami H., et al. Prediction Model of Amyotrophic Lateral Sclerosis by Deep Learning with Patient Induced Pluripotent Stem Cells. Ann. Neurol. 2021;89:1226&#x2013;1233. doi: 10.1002/ana.26047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26047</ArticleId><ArticleId IdType="pmc">PMC8247989</ArticleId><ArticleId IdType="pubmed">33565152</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>